| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H22ClNO4 |
| Molecular Weight | 327.803 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1
InChI
InChIKey=CXQGFLBVUNUQIA-UHFFFAOYSA-N
InChI=1S/C16H22ClNO4/c1-16(2,22-13-9-7-12(17)8-10-13)15(20)21-11-5-6-14(19)18(3)4/h7-10H,5-6,11H2,1-4H3
| Molecular Formula | C16H22ClNO4 |
| Molecular Weight | 327.803 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Clofibride is a hypolipaemic drug of p-chlorophenoxyisobutyric type. Clofibride hypolipaemic effects could be due, partially, to a reduction of hormono-dependent lipolysis. Clofibride decreased blood cholesterol and total lipids, increased liver weight and liver catalase content, and decreased biliary excretion of cholesterol in normolipidemic rats after a 7 day treatment.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Healthy volunteers received therapeutic doses of clofibrate as 2x500 mg capsules, clofibride as 2x450 mg capsules, twice daily for ten days.
Route of Administration:
Oral
